A promising therapeutic strategy for metastatic gestational trophoblastic disease: Engineered anticancer gene‑expressing stem cells to selectively target choriocarcinoma (Review)

Kim,Gyu‑Sik; Hwang,Kyung‑A; Choi,Kyung‑Chul

doi:10.3892/ol.2019.9911

A promising therapeutic strategy for metastatic gestational trophoblastic disease: Engineered anticancer gene‑expressing stem cells to selectively target choriocarcinoma (Review)

Authors:
- Gyu‑Sik Kim
- Kyung‑A Hwang
- Kyung‑Chul Choi
View Affiliations

Affiliations: Laboratory of Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University, Cheongju, North Chungcheong 28644, Republic of Korea
Published online on: January 9, 2019 https://doi.org/10.3892/ol.2019.9911
Pages: 2576-2582

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gestational trophoblastic disease (GTD) is an unusual disease occurring in pregnancy that originates from abnormal trophoblastic cells and comprises a group of diseases with different properties of invasion, metastasis and recurrence. The GTD group includes hydatidiform moles and gestational trophoblastic neoplasms (GTNs), with GTNs being divided into invasive moles, choriocarcinoma, placental site trophoblastic tumors and epithelioid trophoblastic tumors. The present review focuses on current effective treatments for GTD, including conventional and novel promising direct enzyme prodrug therapies (DEPTs). Conventional therapies, such as chemotherapy and hysterectomy, are currently used in a clinical setting; however, the use of diverse DEPTs, including antibody‑DEPT and gene‑DEPT is also being attempted to cure GTNs. In addition, gene delivery tools using genetically engineered neural stem cells (NSCs) are presently being examined for the treatment of GTNs. The tumor‑tropism of NSCs by chemoattractant factors is a unique characteristic of these cells and can serve as a vehicle to deliver anticancer agents. Previous studies have demonstrated that injection with NSC‑expressing suicide genes into xenograft animal models has a significant inhibitory effect on tumor growth. Stem cells can be genetically engineered to express anticancer genes, which migrate to the metastatic sites and selectively target cancer cells, and are considered to effectively target metastatic GTNs. However, the safety issue of stem cell therapy, such as tumorigenesis, remains a challenge. Novel therapies comprising a combination of conventional and novel promising treatments are anticipated to be definitive treatments for metastasized and/or recurrent patients with GTNs.

View Figures

View References

1	Sun P, Wu Q, Ruan G, Zheng X, Song Y, Zhun J, Wu L and Gotlieb WH: Expression patterns of maspin and mutant p53 are associated with the development of gestational trophoblastic neoplasia. Oncol Lett. 12:3135–3142. 2016. View Article : Google Scholar : PubMed/NCBI
2	Savage P, Williams J, Wong SL, Short D, Casalboni S, Catalano K and Seckl M: The demographics of molar pregnancies in England and Wales from 2000–2009. J Reprod Med. 55:341–345. 2010.PubMed/NCBI
3	Begum SA, Bhuiyan ZR, Akther R, Afroz R, Chowdhury A and Keya KA: A review on gestational trophoblastic disease. Bangladesh Med J. 44:2015.
4	Gestational Trophoblastic Disease Treatment (PDQ^®). Health Professional Version. In: PDQ Cancer Information Summaries [Internet]. National Cancer Institute (US). (Bethesda, MD). 2002.
5	Horowitz NS, Goldstein DP and Berkowitz RS: Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities. Gynecol Oncol. 144:208–214. 2017. View Article : Google Scholar : PubMed/NCBI
6	Lee YJ, Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT and Nam JH: Comparing and evaluating the efficacy of methotrexate and actinomycin D as first-line single chemotherapy agents in low risk gestational trophoblastic disease. J Gynecol Oncol. 28:e82017. View Article : Google Scholar : PubMed/NCBI
7	May T, Goldstein DP and Berkowitz RS: Current chemotherapeutic management of patients with gestational trophoblastic neoplasia. Chemother Res Pract. 2011:8062562011.PubMed/NCBI
8	Guo J, Zhong C, Liu Q, Xu J, Zheng Y, Xu S, Gao Y, Guo Y, Wang Y, Luo Q, et al: Intracranial choriocarcinoma occurrence in males: Two cases and a review of the literature. Oncol Lett. 6:1329–1332. 2013. View Article : Google Scholar : PubMed/NCBI
9	Tian Q, Xue Y, Zheng W, Sun R, Ji W, Wang X and An R: Overexpression of hypoxia-inducible factor 1α induces migration and invasion through Notch signaling. Int J Oncol. 47:728–738. 2015. View Article : Google Scholar : PubMed/NCBI
10	Seckl MJ, Sebire NJ and Berkowitz RS: Gestational trophoblastic disease. Lancet. 376:717–729. 2010. View Article : Google Scholar : PubMed/NCBI
11	Lurain JR: Gestational trophoblastic disease I: Epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 203:531–539. 2010. View Article : Google Scholar : PubMed/NCBI
12	Lima LL, Parente RC and Maestá I: Amim Junior J, de Rezende Filho JF, Montenegro CA and Braga A: Clinical and radiological correlations in patients with gestational trophoblastic disease. Radiol Bras. 49:241–250. 2016. View Article : Google Scholar : PubMed/NCBI
13	Soper JT: Gestational trophoblastic disease. Obstet Gynecol. 108:176–187. 2006. View Article : Google Scholar : PubMed/NCBI
14	Ghaemmaghami F, Behtash N, Soleimani K and Hanjani P: Management of patients with metastatic gestational trophoblastic tumor. Gynecol Oncol. 94:187–190. 2004. View Article : Google Scholar : PubMed/NCBI
15	FIGO Committee on Gynecologic Oncology: Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 105:3–4. 2009. View Article : Google Scholar : PubMed/NCBI
16	Chen Y, Qian H, Wang H, Zhang X, Fu M, Liang X, Ma Y, Zhan Q, Lin C and Xiang Y: Ad-PUMA sensitizes drug-resistant choriocarcinoma cells to chemotherapeutic agents. Gynecol Oncol. 107:505–512. 2007. View Article : Google Scholar : PubMed/NCBI
17	Suksai M, Suwanrath C, Kor-Anantakul O, Geater A, Hanprasertpong T, Atjimakul T and Pichatechaiyoot A: Complete hydatidiform mole with co-existing fetus: Predictors of live birth. Eur J Obstet Gynecol Reprod Biol. 212:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
18	Schwentner L, Schmitt W, Bartusek G, Kreienberg R and Herr D: Cervical hydatidiform mole pregnancy after missed abortion presenting with severe vaginal bleeding: Case report and review of the literature. Eur J Obstet Gynecol Reprod Biol. 156:9–11. 2011. View Article : Google Scholar : PubMed/NCBI
19	Tse KY and Ngan HY: Gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol. 26:357–370. 2012. View Article : Google Scholar : PubMed/NCBI
20	McDonald TW and Ruffolo EH: Modern management of gestational trophoblastic disease. Obstet Gynecol Surv. 38:67–83. 1983. View Article : Google Scholar : PubMed/NCBI
21	Ozalp SS, Telli E, Oge T, Tulunay G, Boran N, Turan T, Yenen M, Kurdoglu Z, Ozler A, Yuce K, et al: Multicenter analysis of gestational trophoblastic neoplasia in Turkey. Asian Pac J Cancer Prev. 15:3625–3628. 2014. View Article : Google Scholar : PubMed/NCBI
22	Akyol A, Şimşek M and Üçer Ö: Giant invasive mole presenting as a cause of abdominopelvic mass in a perimenopausal woman: An unusual presentation of a rare pathology. Obstet Gynecol Sci. 59:548–553. 2016. View Article : Google Scholar : PubMed/NCBI
23	Garner EI, Goldstein DP, Feltmate CM and Berkowitz RS: Gestational trophoblastic disease. Clin Obstet Gynecol. 50:112–122. 2007. View Article : Google Scholar : PubMed/NCBI
24	Ibi T, Hirai K, Bessho R, Kawamoto M, Koizumi K and Shimizu K: Choriocarcinoma of the lung: Report of a case. Gen Thorac Cardiovasc Surg. 60:377–380. 2012. View Article : Google Scholar : PubMed/NCBI
25	Berkowitz RS and Goldstein DP: Current management of gestational trophoblastic diseases. Gynecol Oncol. 112:654–662. 2009. View Article : Google Scholar : PubMed/NCBI
26	Monchek R and Wiedaseck S: Gestational trophoblastic disease: An overview. J Midwifery Womens Health. 57:255–259. 2012. View Article : Google Scholar : PubMed/NCBI
27	Shih IM and Kurman RJ: The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gynecol Pathol. 20:31–47. 2001. View Article : Google Scholar : PubMed/NCBI
28	Scully RE and Young RH: Trophoblastic pseudotumor: A reappraisal. Am J Surg Pathol. 5:75–76. 1981. View Article : Google Scholar : PubMed/NCBI
29	Behnamfar F, Rouholamin S and Esteki M: Presentation of Placental Site Trophoblastic Tumor with Amenorrhea. Adv Biomed Res. 6:292017. View Article : Google Scholar : PubMed/NCBI
30	Eckstein RP, Paradinas FJ and Bagshawe KD: Placental site trophoblastic tumour (trophoblastic pseudotumour): A study of four cases requiring hysterectomy including one fatal case. Histopathology. 6:211–226. 1982. View Article : Google Scholar : PubMed/NCBI
31	Newlands ES, Mulholland PJ, Holden L, Seckl MJ and Rustin GJ: Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol. 18:854–859. 2000. View Article : Google Scholar : PubMed/NCBI
32	Park JW and Bae JW: Epithelioid Trophoblastic Tumor in a Postmenopausal Woman: A Case Report. J Menopausal Med. 22:50–53. 2016. View Article : Google Scholar : PubMed/NCBI
33	Rodríguez-Trujillo A, Martínez-Serrano MJ, Saco A and Torné A: Two cases of epithelioid trophoblastic tumors in postmenopausal women. Menopause. 24:1304–1308. 2017. View Article : Google Scholar : PubMed/NCBI
34	Davis MR, Howitt BE, Quade BJ, Crum CP, Horowitz NS, Goldstein DP and Berkowitz RS: Epithelioid trophoblastic tumor: A single institution case series at the New England Trophoblastic Disease Center. Gynecol Oncol. 137:456–461. 2015. View Article : Google Scholar : PubMed/NCBI
35	Kim JH, Lee SK, Hwang SH, Kim JS, Yoon G, Lee YY, Kim TJ, Choi CH, Kim BG, Bae DS, et al: Extrauterine epithelioid trophoblastic tumor in hysterectomized woman. Obstet Gynecol Sci. 60:124–128. 2017. View Article : Google Scholar : PubMed/NCBI
36	Abrão RA, de Andrade JM, Tiezzi DG, Marana HR, Candido dos Reis FJ and Clagnan WS: Treatment for low-risk gestational trophoblastic disease: Comparison of single-agent methotrexate, dactinomycin and combination regimens. Gynecol Oncol. 108:149–153. 2008. View Article : Google Scholar : PubMed/NCBI
37	Lima LLA, Padron L, Câmara R, Sun SY, Rezende J and Braga A: The role of surgery in the management of women with gestational trophoblastic disease. Rev Col Bras Cir. 44:94–101. 2017. View Article : Google Scholar : PubMed/NCBI
38	Eoh KJ, Chung YS, Yim GW, Nam EJ, Kim S, Kim SW and Kim YT: Role of surgical therapy in the management of gestational trophoblastic neoplasia. Obstet Gynecol Sci. 58:277–283. 2015. View Article : Google Scholar : PubMed/NCBI
39	Berkowitz RS and Goldstein DP: Clinical practice. Molar pregnancy. N Engl J Med. 360:1639–1645. 2009. View Article : Google Scholar : PubMed/NCBI
40	Hurteau JA: Gestational trophoblastic disease: Management of hydatidiform mole. Clin Obstet Gynecol. 46:557–569. 2003. View Article : Google Scholar : PubMed/NCBI
41	Gerulath AH, Ehlen TG, Bessette P, Jolicoeur L and Savoie R;: Society of Obstetricians and Gynaecologists of CanadaGynaecologic Oncologists of Canada; Society of Canadian Colposcopists: Gestational trophoblastic disease. J Obstet Gynaecol Can. 24:434–446. 2002.(In English; French). PubMed/NCBI
42	Sebire NJ and Seckl MJ: Gestational trophoblastic disease: Current management of hydatidiform mole. BMJ. 337:a11932008. View Article : Google Scholar : PubMed/NCBI
43	Kang WD, Choi HS and Kim SM: Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 117:477–480. 2010. View Article : Google Scholar : PubMed/NCBI
44	De Vos M, Leunen M, Fontaine C and De Sutter P: Successful Primary Treatment of a Hydatidiform Mole with Methotrexate and EMA/CO. Case Rep Med. 2009:4541612009. View Article : Google Scholar : PubMed/NCBI
45	Shanbhogue AK, Lalwani N and Menias CO: Gestational trophoblastic disease. Radiol Clin North Am. 51:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
46	Wenzel L, Berkowitz RS, Newlands E, Hancock B, Goldstein DP, Seckl MJ, Habbal R, Bernstein M, Kluhsman B, Kulchak-Rahm A, et al: Quality of life after gestational trophoblastic disease. J Reprod Med. 47:387–394. 2002.PubMed/NCBI
47	Lurain JR: Gestational trophoblastic disease II: Classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 204:11–18. 2011. View Article : Google Scholar : PubMed/NCBI
48	Karjoo Z, Chen X and Hatefi A: Progress and problems with the use of suicide genes for targeted cancer therapy. Adv Drug Deliv Rev. 99(Pt A): 113–128. 2016. View Article : Google Scholar : PubMed/NCBI
49	Zawilska JB, Wojcieszak J and Olejniczak AB: Prodrugs: a challenge for the drug development. Pharmacol Rep. 65:1–14. 2013. View Article : Google Scholar : PubMed/NCBI
50	Schellmann N, Deckert PM, Bachran D, Fuchs H and Bachran C: Targeted enzyme prodrug therapies. Mini Rev Med Chem. 10:887–904. 2010. View Article : Google Scholar : PubMed/NCBI
51	Springer CJ, Bagshawe KD, Sharma SK, Searle F, Boden JA, Antoniw P, Burke PJ, Rogers GT, Sherwood RF and Melton RG: Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur J Cancer. 27:1361–1366. 1991. View Article : Google Scholar : PubMed/NCBI
52	Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG and Sherwood RF: A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer. 58:700–703. 1988. View Article : Google Scholar : PubMed/NCBI
53	Zhang J, Kale V and Chen M: Gene-directed enzyme prodrug therapy. AAPS J. 17:102–110. 2015. View Article : Google Scholar : PubMed/NCBI
54	Weyel D, Sedlacek HH, Müller R and Brüsselbach S: Secreted human beta-glucuronidase: A novel tool for gene-directed enzyme prodrug therapy. Gene Ther. 7:224–231. 2000. View Article : Google Scholar : PubMed/NCBI
55	Alenzi FQ, Lotfy M, Tamimi WG and Wyse RK: Review: Stem cells and gene therapy. Lab Hematol. 16:53–73. 2010. View Article : Google Scholar : PubMed/NCBI
56	Müller FJ, Snyder EY and Loring JF: Gene therapy: Can neural stem cells deliver? Nat Rev Neurosci. 7:75–84. 2006. View Article : Google Scholar : PubMed/NCBI
57	Benedetti S, Pirola B, Pollo B, Magrassi L, Bruzzone MG, Rigamonti D, Galli R, Selleri S, Di Meco F, De Fraja C, et al: Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med. 6:447–450. 2000. View Article : Google Scholar : PubMed/NCBI
58	Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, et al: Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas. Proc Natl Acad Sci USA. 97:12846–12851. 2000. View Article : Google Scholar : PubMed/NCBI
59	Ahmed AU, Alexiades NG and Lesniak MS: The use of neural stem cells in cancer gene therapy: Predicting the path to the clinic. Curr Opin Mol Ther. 12:546–552. 2010.PubMed/NCBI
60	Consiglio A, Gritti A, Dolcetta D, Follenzi A, Bordignon C, Gage FH, Vescovi AL and Naldini L: Robust in vivo gene transfer into adult mammalian neural stem cells by lentiviral vectors. Proc Natl Acad Sci USA. 101:14835–14840. 2004. View Article : Google Scholar : PubMed/NCBI
61	Heo JR, Kim NH, Cho J and Choi KC: Current treatments for advanced melanoma and introduction of a promising novel gene therapy for melanoma (Review). Oncol Rep. 36:1779–1786. 2016. View Article : Google Scholar : PubMed/NCBI
62	Zhao D, Najbauer J, Garcia E, Metz MZ, Gutova M, Glackin CA, Kim SU and Aboody KS: Neural stem cell tropism to glioma: Critical role of tumor hypoxia. Mol Cancer Res. 6:1819–1829. 2008. View Article : Google Scholar : PubMed/NCBI
63	Yi BR, Hwang KA, Aboody KS, Jeung EB, Kim SU and Choi KC: Selective antitumor effect of neural stem cells expressing cytosine deaminase and interferon-beta against ductal breast cancer cells in cellular and xenograft models. Stem Cell Res (Amst). 12:36–48. 2014. View Article : Google Scholar
64	Yi BR, Kim SU and Choi KC: Co-treatment with therapeutic neural stem cells expressing carboxyl esterase and CPT-11 inhibit growth of primary and metastatic lung cancers in mice. Oncotarget. 5:12835–12848. 2014. View Article : Google Scholar : PubMed/NCBI
65	Magge SN, Malik SZ, Royo NC, Chen HI, Yu L, Snyder EY, O'Rourke DM and Watson DJ: Role of monocyte chemoattractant protein-1 (MCP-1/CCL2) in migration of neural progenitor cells toward glial tumors. J Neurosci Res. 87:1547–1555. 2009. View Article : Google Scholar : PubMed/NCBI
66	Bonini C, Bondanza A, Perna SK, Kaneko S, Traversari C, Ciceri F and Bordignon C: The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther. 15:1248–1252. 2007. View Article : Google Scholar : PubMed/NCBI
67	Joo KM, Park IH, Shin JY, Jin J, Kang BG, Kim MH, Lee SJ, Jo MY, Kim SU and Nam DH: Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol Ther. 17:570–575. 2009. View Article : Google Scholar : PubMed/NCBI
68	Green LK, Storey MA, Williams EM, Patterson AV, Smaill JB, Copp JN and Ackerley DF: The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy. Cancers (Basel). 5:985–997. 2013. View Article : Google Scholar : PubMed/NCBI
69	Park GT, Kim SU and Choi KC: Anti-proliferative Effect of Engineered Neural Stem Cells Expressing Cytosine Deaminase and Interferon-beta against Lymph Node-Derived Metastatic Colorectal Adenocarcinoma in Cellular and Xenograft Mouse Models. Cancer Res Treat. 49:79–91. 2017. View Article : Google Scholar : PubMed/NCBI
70	Xie Y, Gilbert JD, Kim JH and Freytag SO: Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy. Clin Cancer Res. 5:4224–4232. 1999.PubMed/NCBI
71	Mahan SD, Ireton GC, Knoeber C, Stoddard BL and Black ME: Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy. Protein Eng Des Sel. 17:625–633. 2004. View Article : Google Scholar : PubMed/NCBI
72	Vermes A, Guchelaar HJ and Dankert J: Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 46:171–179. 2000. View Article : Google Scholar : PubMed/NCBI
73	Ardiani A, Johnson AJ, Ruan H, Sanchez-Bonilla M, Serve K and Black ME: Enzymes to die for: Exploiting nucleotide metabolizing enzymes for cancer gene therapy. Curr Gene Ther. 12:77–91. 2012. View Article : Google Scholar : PubMed/NCBI
74	Kim DJ, Yi BR, Lee HR, Kim SU and Choi KC: Pancreatic tumor mass in a xenograft mouse model is decreased by treatment with therapeutic stem cells following introduction of therapeutic genes. Oncol Rep. 30:1129–1136. 2013. View Article : Google Scholar : PubMed/NCBI
75	Yi BR, Park MA, Lee HR, Kang NH, Choi KJ, Kim SU and Choi KC: Suppression of the growth of human colorectal cancer cells by therapeutic stem cells expressing cytosine deaminase and interferon-β via their tumor-tropic effect in cellular and xenograft mouse models. Mol Oncol. 7:543–554. 2013. View Article : Google Scholar : PubMed/NCBI
76	Yi BR, Kim SU and Choi KC: Additional effects of engineered stem cells expressing a therapeutic gene and interferon-β in a xenograft mouse model of endometrial cancer. Int J Oncol. 47:171–178. 2015. View Article : Google Scholar : PubMed/NCBI
77	Panelli MC and Marincola FM: Immunotherapy update: from interleukin-2 to antigen-specific therapy. ASCO educational book. Perry MC: American Society of Clinical Oncology. 467–473. 1998.
78	Kim GS, Heo JR, Kim SU and Choi KC: Cancer-Specific Inhibitory Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-β Against Choriocarcinoma in Xenografted Metastatic Mouse Models. Transl Oncol. 11:74–85. 2018. View Article : Google Scholar : PubMed/NCBI
79	Zwaka TP: Use of Genetically Modified Stem Cells in Experimental Gene Therapies. National Institutes of Health (US). (Bethesda, MD). 2006.
80	Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL and Yu JS: The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res. 62:5657–5663. 2002.PubMed/NCBI
81	Yuan X, Hu J, Belladonna ML, Black KL and Yu JS: Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. CancerRes. 66:2630–2638. 2006.